Biotech Values

[oc631]

many docs might elect to simply wait if the first-to-market interferon free combo isn't top notch.

If the first approved oral therapy has higher SVR rates than existing SOC in treatment-naive patients I feel the majority of doctors will begin testing the drug on the backlog of patients at their practice. Their personal experience with the drug will dictate future use. Most patients are tired of waiting and living with the knowledge that they are infected with this virus. Patients failing therapy will have a second chance to be re-treated with different classes of DAA's or perhaps a potent DAA/DAA combo with interferon/interferon lambda at a future date.